CRISPR Therapeutics(US:CRSP) ZACKS·2026-01-15 23:51Company Performance - CRISPR Therapeutics AG closed at $54.21, reflecting a -4.71% change from the previous day, underperforming compared to the S&P 500's daily gain of 0.26% [1] - Prior to the recent trading session, the company's shares had increased by 3.93%, surpassing the Medical sector's gain of 0.92% and the S&P 500's gain of 1.57% [1] Earnings Forecast - The upcoming earnings disclosure is expected to show an EPS of -$1.15, indicating a significant 161.36% decline from the same quarter last year [2] - Revenue is forecasted at $4 million, representing an 88.78% decrease compared to the same quarter last year [2] - For the full year, the Zacks Consensus Estimates predict an EPS of -$6.33 and revenue of $8.54 million, reflecting changes of -45.85% and 0% respectively from the prior year [3] Analyst Estimates and Rankings - Changes in analyst estimates for CRISPR Therapeutics AG are crucial as they reflect short-term business trends, with positive revisions indicating a favorable outlook on business health and profitability [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with stocks rated 1 achieving an average annual return of +25% since 1988 [6] - Currently, CRISPR Therapeutics AG holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate having increased by 0.17% over the past month [6] Industry Overview - The Medical - Biomedical and Genetics industry, which includes CRISPR Therapeutics AG, has a Zacks Industry Rank of 100, placing it in the top 41% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]